JP2016520542A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520542A5 JP2016520542A5 JP2016505600A JP2016505600A JP2016520542A5 JP 2016520542 A5 JP2016520542 A5 JP 2016520542A5 JP 2016505600 A JP2016505600 A JP 2016505600A JP 2016505600 A JP2016505600 A JP 2016505600A JP 2016520542 A5 JP2016520542 A5 JP 2016520542A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- antibody
- item
- antigen
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 111
- 230000000295 complement effect Effects 0.000 claims description 47
- 210000002966 serum Anatomy 0.000 claims description 45
- 239000012634 fragment Substances 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 29
- 108091007433 antigens Proteins 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 20
- 108020004999 messenger RNA Proteins 0.000 claims description 16
- 206010047115 Vasculitis Diseases 0.000 claims description 15
- 230000000692 anti-sense effect Effects 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims description 12
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 12
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 12
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 12
- 208000011038 Cold agglutinin disease Diseases 0.000 claims description 10
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims description 10
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 10
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 10
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 10
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 10
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 10
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 208000002780 macular degeneration Diseases 0.000 claims description 10
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 10
- 206010000234 Abortion spontaneous Diseases 0.000 claims description 9
- 208000000995 spontaneous abortion Diseases 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 208000023328 Basedow disease Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
- 208000015023 Graves' disease Diseases 0.000 claims description 5
- 206010018910 Haemolysis Diseases 0.000 claims description 5
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 5
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims description 5
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 5
- 241000721454 Pemphigus Species 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 108010079723 Shiga Toxin Proteins 0.000 claims description 5
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 5
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 5
- 230000001086 cytosolic effect Effects 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 201000001981 dermatomyositis Diseases 0.000 claims description 5
- 238000001631 haemodialysis Methods 0.000 claims description 5
- 230000000322 hemodialysis Effects 0.000 claims description 5
- 230000008588 hemolysis Effects 0.000 claims description 5
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 230000009529 traumatic brain injury Effects 0.000 claims description 5
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 229960002224 eculizumab Drugs 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 208000015994 miscarriage Diseases 0.000 claims description 4
- 229950003203 pexelizumab Drugs 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims 4
- 206010028372 Muscular weakness Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 230000036473 myasthenia Effects 0.000 claims 2
- 238000004062 sedimentation Methods 0.000 claims 2
- 208000008899 Habitual abortion Diseases 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000034213 recurrent susceptibility to 1 pregnancy loss Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 description 66
- 150000001875 compounds Chemical class 0.000 description 63
- 230000007423 decrease Effects 0.000 description 9
- 230000007774 longterm Effects 0.000 description 4
- 101150069146 C5 gene Proteins 0.000 description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 101150081011 ssl7 gene Proteins 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361806687P | 2013-03-29 | 2013-03-29 | |
| US61/806,687 | 2013-03-29 | ||
| PCT/US2014/032209 WO2014160958A1 (en) | 2013-03-29 | 2014-03-28 | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018080510A Division JP6505288B2 (ja) | 2013-03-29 | 2018-04-19 | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520542A JP2016520542A (ja) | 2016-07-14 |
| JP2016520542A5 true JP2016520542A5 (OSRAM) | 2017-04-27 |
| JP6505079B2 JP6505079B2 (ja) | 2019-04-24 |
Family
ID=50686201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016505600A Active JP6505079B2 (ja) | 2013-03-29 | 2014-03-28 | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
| JP2018080510A Active JP6505288B2 (ja) | 2013-03-29 | 2018-04-19 | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018080510A Active JP6505288B2 (ja) | 2013-03-29 | 2018-04-19 | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20160051673A1 (OSRAM) |
| EP (2) | EP2978451B1 (OSRAM) |
| JP (2) | JP6505079B2 (OSRAM) |
| CA (1) | CA2897334A1 (OSRAM) |
| ES (1) | ES2768648T3 (OSRAM) |
| WO (1) | WO2014160958A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2006381B1 (en) | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
| CA2700701C (en) | 2007-09-26 | 2020-12-29 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| NZ717429A (en) | 2008-04-11 | 2018-07-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| PL2970974T3 (pl) | 2013-03-14 | 2018-01-31 | Alnylam Pharmaceuticals Inc | Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania |
| WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| KR102650420B1 (ko) | 2014-12-19 | 2024-03-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| TWI617580B (zh) | 2014-12-19 | 2018-03-11 | 中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| US20180142010A1 (en) * | 2015-06-26 | 2018-05-24 | Alexion Pharmaceuticals, Inc. | Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| EP4462121A3 (en) * | 2015-09-11 | 2025-01-22 | Alexion Pharmaceuticals, Inc. | Recombinant glycosylated eculizumab and eculizumab variants |
| EP4374922A3 (en) | 2016-06-14 | 2024-08-28 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| EA201990018A1 (ru) * | 2016-06-17 | 2019-08-30 | Чугаи Сейяку Кабусики Кайся | Антитела к с5 и способы их применения |
| TW202300168A (zh) | 2016-08-05 | 2023-01-01 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
| ES2888904T3 (es) * | 2016-10-19 | 2022-01-10 | Alexion Pharma Inc | Un método de cuantificación de C5a sin unir en una muestra |
| ES2848206T3 (es) | 2016-10-19 | 2021-08-05 | Alexion Pharma Inc | Un método de cuantificar C5 sin unir en una muestra |
| KR101949891B1 (ko) * | 2017-01-31 | 2019-02-19 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
| DK3612208T5 (da) * | 2017-04-21 | 2024-09-02 | Volution Immuno Pharmaceuticals Sa | Coversin til behandlingen af autoimmune sygdomme med blisterdannelse |
| SG11202004662RA (en) | 2017-12-13 | 2020-06-29 | Regeneron Pharma | Anti-c5 antibody combinations and uses thereof |
| EP3597222A1 (en) * | 2018-07-16 | 2020-01-22 | Easemedcontrol R & D GmbH & Co KG | Treatment and diagnosis of unresolved inflammatory diseases |
| CN113038967A (zh) * | 2018-09-06 | 2021-06-25 | 宾夕法尼亚大学理事会 | 人源化抗c5抗体及其用途 |
| WO2020219922A1 (en) * | 2019-04-24 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof |
| WO2021154941A1 (en) * | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
| WO2023064809A1 (en) * | 2021-10-12 | 2023-04-20 | Vanqua Bio, Inc. | Oligonucleotides for targeting complement c5 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US20030143204A1 (en) | 2001-07-27 | 2003-07-31 | Lewis David L. | Inhibition of RNA function by delivery of inhibitors to animal cells |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
| US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
| AU2001266557A1 (en) | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| AU2002333554C1 (en) | 2001-09-12 | 2008-12-11 | Becton, Dickinson And Company | Microneedle-based pen device for drug delivery and method for using same |
| EP1572902B1 (en) | 2002-02-01 | 2014-06-11 | Life Technologies Corporation | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| US7556944B2 (en) | 2002-05-03 | 2009-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for use in preparing siRNAs |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| ATE435303T1 (de) | 2002-08-12 | 2009-07-15 | New England Biolabs Inc | Verfahren und zusammensetzungen in verbindung mit gen-silencing |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| EP3736335A1 (en) | 2004-02-12 | 2020-11-11 | Archemix LLC | Aptamer therapeutics useful in the treatment of complement-related disorders |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| SG172686A1 (en) * | 2006-03-08 | 2011-07-28 | Archemix Corp | Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
| CA3022097C (en) * | 2006-03-15 | 2020-10-27 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| EP2173380A4 (en) | 2007-07-13 | 2011-08-31 | Abbott Biotech Ltd | METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER |
| NZ717429A (en) | 2008-04-11 | 2018-07-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| PT2328616E (pt) | 2008-08-05 | 2015-08-26 | Novartis Ag | Composições e métodos para anticorpos dirigidos à proteína c5 do complemento |
| AU2009313203B2 (en) | 2008-11-10 | 2015-08-27 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| US20100291106A1 (en) | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| NZ597259A (en) | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| MX2012010116A (es) | 2010-03-01 | 2013-02-26 | Alexion Pharma Inc | Metodos y composiciones para el tratamiento de la enfermedad de degos. |
| PL2970974T3 (pl) | 2013-03-14 | 2018-01-31 | Alnylam Pharmaceuticals Inc | Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania |
-
2014
- 2014-03-28 US US14/779,605 patent/US20160051673A1/en not_active Abandoned
- 2014-03-28 EP EP14722916.5A patent/EP2978451B1/en not_active Revoked
- 2014-03-28 JP JP2016505600A patent/JP6505079B2/ja active Active
- 2014-03-28 ES ES14722916T patent/ES2768648T3/es active Active
- 2014-03-28 EP EP18211716.8A patent/EP3473272A1/en not_active Withdrawn
- 2014-03-28 CA CA2897334A patent/CA2897334A1/en not_active Abandoned
- 2014-03-28 WO PCT/US2014/032209 patent/WO2014160958A1/en not_active Ceased
-
2018
- 2018-04-19 JP JP2018080510A patent/JP6505288B2/ja active Active
-
2019
- 2019-05-29 US US16/425,402 patent/US20200023060A1/en not_active Abandoned
-
2023
- 2023-10-06 US US18/482,159 patent/US20240293540A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520542A5 (OSRAM) | ||
| JP2024107240A (ja) | 補体関連障害を処置するための方法および組成物 | |
| Durey et al. | Anti-complement-factor H-associated glomerulopathies | |
| Brocklebank et al. | Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea | |
| TWI848905B (zh) | 用於治療補體介導之疾病及病症之方法 | |
| JP2021501134A5 (OSRAM) | ||
| KR20120105405A (ko) | 보체 단백질에 결합하는 이중특이적 항체 | |
| JP2016525139A5 (OSRAM) | ||
| AU2018201961B2 (en) | Methods and compositions for treating complement-associated disorders | |
| JP2021178857A (ja) | Ｈ因子を強化する抗体及びその用途 | |
| Lee et al. | A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II | |
| CN117940160A (zh) | α-烯醇酶拮抗剂在治疗纤维化疾病中的用途 | |
| Baumann et al. | The role of Fc receptors and complement in autoimmunity | |
| JPWO2021076991A5 (OSRAM) | ||
| JP2018502598A5 (OSRAM) |